VEGFA and neoplasm: Mechanistically, ASP-3 was found to effectively reduce vascular endothelial growth factor receptor (VEGFR) 2 phosphorylation (p-VEGFR2) in tumor cells and affect the vascular endothelial growth factor (VEGF) signaling pathway.